Sabine Jung-Imhof

Title: Sabine Jung-Imhof: Innovator in Bispecific Antibodies

Introduction

Sabine Jung-Imhof is a prominent inventor based in Planegg, Germany. She has made significant contributions to the field of biopharmaceuticals, particularly in the development of bispecific antibodies. With a total of 2 patents, her work is paving the way for innovative treatments in cancer therapy.

Latest Patents

Her latest patents include bispecific antibodies against CD3EPSILON and ROR1. This invention relates to the manufacture and use of these antibodies, which target ROR1 and CD3. Another notable patent involves bispecific antibodies against CD3 and BCMA. This invention describes a bispecific bi- or trivalent antibody that specifically binds to the extracellular domain of human B cell maturation antigen (BCMA) and human CD3. The patent details specific amino acid substitutions in the constant domains of the antibody, enhancing its therapeutic potential.

Career Highlights

Throughout her career, Sabine has worked with notable companies such as Engmab AG and Bristol-Myers Squibb Company. Her experience in these organizations has contributed to her expertise in antibody development and biopharmaceutical research.

Collaborations

Sabine has collaborated with esteemed colleagues, including Minh Diem Vu and Klaus Strein. These partnerships have further enriched her research and innovation in the field.

Conclusion

Sabine Jung-Imhof is a trailblazer in the development of bispecific antibodies, with her patents reflecting her commitment to advancing medical science. Her work continues to inspire future innovations in biopharmaceuticals.